Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kaye

Showing results (761-770 of 853) with videos related to

Pageof 86
Sort By:
British Journal of Cancer|October 27, 2012
Association of creatine kinase and skin toxicity in phase I trials of anticancer agentsV Moreno Garcia, P Thavasu, M Blanco Codesido, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2014
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumorsRobin L Jones, Edward S Kim, Pilar Nava-Parada, et al.
Acta Ophthalmologica|December 30, 2020
Tomographic and aberrometric assessment of first-time diagnosed paediatric keratoconus based on age ranges: a multicentre studyCarlos Rocha-de-Lossada, Mario Prieto-Godoy, José-María Sánchez-González, et al.
Journal of Tissue Engineering|March 1, 2021
Biomaterials for corneal endothelial cell culture and tissue engineeringMohit Parekh, Vito Romano, Kareem Hassanin, et al.
British Journal of Cancer|January 1, 1997
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancerR de Wit, R Sylvester, C Tsitsa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United KingdomS D Fosså, S B Kaye, G M Mead, et al.
BMJ Open Ophthalmology|April 23, 2024
Microbial keratitis in Southern Malawi: a microbiological pilot studyTobi F Somerville, Shaffi Mdala, Thokozani Zungu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2009
A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcomaJ E Ang, R N Shah, M Everard, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international surveyXavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor typesJ Baselga, D Rischin, M Ranson, et al.
Pageof 86

Showing results (761-770 of 853) with videos related to

Sort By:
Pageof 86
British Journal of Cancer|October 27, 2012
Association of creatine kinase and skin toxicity in phase I trials of anticancer agentsV Moreno Garcia, P Thavasu, M Blanco Codesido, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2014
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumorsRobin L Jones, Edward S Kim, Pilar Nava-Parada, et al.
Acta Ophthalmologica|December 30, 2020
Tomographic and aberrometric assessment of first-time diagnosed paediatric keratoconus based on age ranges: a multicentre studyCarlos Rocha-de-Lossada, Mario Prieto-Godoy, José-María Sánchez-González, et al.
Journal of Tissue Engineering|March 1, 2021
Biomaterials for corneal endothelial cell culture and tissue engineeringMohit Parekh, Vito Romano, Kareem Hassanin, et al.
British Journal of Cancer|January 1, 1997
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancerR de Wit, R Sylvester, C Tsitsa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United KingdomS D Fosså, S B Kaye, G M Mead, et al.
BMJ Open Ophthalmology|April 23, 2024
Microbial keratitis in Southern Malawi: a microbiological pilot studyTobi F Somerville, Shaffi Mdala, Thokozani Zungu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2009
A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcomaJ E Ang, R N Shah, M Everard, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international surveyXavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor typesJ Baselga, D Rischin, M Ranson, et al.
Pageof 86